.STUDY HIGHLIGHT.16 Oct 2024.
In the NIAGARA trial, the enhancement of perioperative durvalumab to conventional therapy for muscle-invasive sac cancer boosted event-free and in general survival, denoting a brand-new therapy alternative for this condition.